123 related articles for article (PubMed ID: 37874253)
1. Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study.
Creuzot Garcher CP; Massin P; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Acta Ophthalmol; 2024 Jun; 102(4):e548-e556. PubMed ID: 37874253
[TBL] [Abstract][Full Text] [Related]
2. Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008-2018: The Nationwide LANDSCAPE Study.
Creuzot Garcher CP; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Ophthalmol Ther; 2023 Oct; 12(5):2687-2701. PubMed ID: 37531029
[TBL] [Abstract][Full Text] [Related]
3. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
4. Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment.
Ceylan A; Dogan ME; Demircan A; Akar Y
Int Ophthalmol; 2022 Nov; 42(11):3579-3588. PubMed ID: 35737210
[TBL] [Abstract][Full Text] [Related]
5. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study.
Billioti de Gage S; Bertrand M; Grimaldi S; Zureik M
Acta Ophthalmol; 2022 Mar; 100(2):e502-e511. PubMed ID: 34126649
[TBL] [Abstract][Full Text] [Related]
11. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
[TBL] [Abstract][Full Text] [Related]
12. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
[No Abstract] [Full Text] [Related]
13. INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study.
Comet A; Gascon P; Ramtohul P; Donnadieu B; Denis D; Matonti F
Eur J Ophthalmol; 2021 Mar; 31(2):754-758. PubMed ID: 32507032
[TBL] [Abstract][Full Text] [Related]
14. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants.
Eandi CM; De Geronimo D; Giannini D; Polito MS; Tosi GM; Neri G; Le Mer Y; Varano M; Parravano M
Acta Diabetol; 2020 Jul; 57(7):867-874. PubMed ID: 32114643
[TBL] [Abstract][Full Text] [Related]
15. Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study.
Wirkkala J; Kubin AM; Ohtonen P; Yliselä J; Siik T; Hautala N
BMC Ophthalmol; 2022 Jun; 22(1):258. PubMed ID: 35681133
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of Treated Diabetes Ocular Complications in France 2008-2018-The LANDSCAPE French Nationwide Study.
Creuzot-Garcher C; Massin P; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365148
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper].
Augustin AJ; Feltgen N; Haritoglou C; Hoerauf H; Maier MM; Mardin CY; Schargus M
Klin Monbl Augenheilkd; 2021 Jan; 238(1):73-84. PubMed ID: 31770786
[TBL] [Abstract][Full Text] [Related]
18. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
[TBL] [Abstract][Full Text] [Related]
20. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(13):1-22. PubMed ID: 23074517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
